Clinical Challenges: Gene Therapy for Inherited Retinal Diseases
The FDA approval of UF's AAV technology in voretigene neparvovec (Luxturna) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy almost 4 years ago marked a turning point in gene therapy.
AavantiBio Furthers Strategic Partnership With University of Florida To Research and Develop Next Generation Gene Therapy Capsids
UF startup and UF Innovate | The Hub resident AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, announced it is partnering with the University of Florida to research and develop next generation gene therapy capsids with the goal of creating safer, more effective, and tissue specific gene therapies.
FDA Includes UF Researcher As Advisory Board Considers Gene Therapy Risks
FDA's Cellular, Tissue, and Gene Therapies Advisory Committee experts prepare for a two-day meeting to talk about high-dose that gene therapy developers and investigators are allowed to give patients in each trial.
StrideBio Announces Closing of $81.5M Series B Financing
StrideBio, Inc., a leading developer of novel engineered adeno-associated virus (AAV) based gene therapies, announced the closing of an oversubscribed Series B funding round, which raised $81.5 million.
Atsena Therapeutics Raises $55 Million Series A Financing to Advance LCA1 Gene Therapy Clinical Program, Two Preclinical Assets, and Novel Capsid Development for Ocular Diseases
UF startup Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, announced it has closed an oversubscribed $55 million Series A financing led by Sofinnova Investments with participation from additional new investors Abingworth and Lightstone Ventures.
Lacerta Therapeutics Signs Gene Therapy Research Partnership With UCB
UF startup and UF Innovate | Sid Martin Biotech alum Lacerta Therapeutics, a clinical-stage gene therapy company, announced a new gene therapy... Read More
Concept Companies Unveils New Office for Lacerta Therapeutics in Alachua’s Copeland Park
Gainesville-based developer Concept Companies has completed construction on a new 12,950-square-foot office and lab building in Copeland Park for UF startup and... Read More
AGTC Boosts AAV Manufacturing Productivity With Herpes Simplex Virus
By using the herpes simplex virus (HSV) as a helper for its adeno-associated viral (AAV) platform UF startup and UF Innovate |... Read More
Ophthotech Expands Gene Therapy Pipeline in Orphan Retinal Diseases with Exclusive Option for Novel Product Candidates to Treat Best Vitelliform Macular Dystrophy (Ophthotech)
Ophthotech Corporation announced that it has entered into an exclusive option agreement with the University of Pennsylvania (Penn) and the University of... Read More
